NEW YORK – Devyser Diagnostics said on Monday that it has entered into an in vitro diagnostic development agreement with Illumina.
The agreement will enable Sweden-based Devyser to advance its next-generation sequencing-based IVD tests on the Illumina MiSeqDx sequencer through regulatory processes in the US and in Europe. Financial and other terms were not disclosed.
"With this agreement, we are taking an important step towards giving more laboratories access to Devyser's simple, fast, and effective genetic testing solutions, and to provide patients with the best possible care," CEO Fredrik Alpsten said in a statement.
In 2023, Devyser signed agreements granting Thermo Fisher Scientific exclusive rights to commercialize and distribute its post-transplant tests in North America, Europe, and Brazil.